P-MOD-501
Ornithine Transcarbamylase (OTC) Deficiency
PreclinicalEarly-stage
Key Facts
Indication
Ornithine Transcarbamylase (OTC) Deficiency
Phase
Preclinical
Status
Early-stage
Company
About Poseida Therapeutics
Poseida Therapeutics was a San Diego-based biotech focused on developing next-generation cell and gene therapies with its non-viral engineering platforms. Its core strategy centered on overcoming the limitations of viral vectors to create CAR-T products with a high proportion of stem cell memory T cells for enhanced persistence and potency. The company advanced a pipeline of autologous and allogeneic CAR-T candidates targeting hematological malignancies and solid tumors. Its significant technological achievements culminated in its acquisition by Roche in 2024, validating its platform and providing a path for accelerated development.
View full company profileTherapeutic Areas
Other Ornithine Transcarbamylase (OTC) Deficiency Drugs
| Drug | Company | Phase |
|---|---|---|
| DTX301 | Ultragenyx Pharmaceutical | Phase 3 |
| ECUR-506 | Precision BioSciences | Phase 1/2 |